The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line (1L) anti-PD-1 plus chemotherapy in HER2-negative advanced gastric cancer: Real-world evidence from a single Korean center.
 
Joosung Gabriel Shim
No Relationships to Disclose
 
Minkyu Jung
Employment - Ensol Biosciences (I)
Stock and Other Ownership Interests - Ensol Biosciences; Ensol Biosciences (I)
Honoraria - Celltrion; Lilly
 
Hyunwook Kim
No Relationships to Disclose
 
Kyoo Hyun Kim
No Relationships to Disclose
 
Taeho Kim
No Relationships to Disclose
 
Youhyun Kim
No Relationships to Disclose
 
Hyo Sup Shim
No Relationships to Disclose
 
Hyunki Kim
No Relationships to Disclose
 
Hyo Song Kim
No Relationships to Disclose
 
Choong-kun Lee
Honoraria - Boryung; Dong-A ST; Novartis; SERVIER
Consulting or Advisory Role - AstraZeneca
 
Sun Young Rha
Consulting or Advisory Role - Aadi; Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks